Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook
1. BSX halts sales of ACURATE neo2 and Prime valves due to regulatory costs. 2. Company remains confident in broader portfolio and financial targets for 2025. 3. 2025 net sales growth projected at 15%-17% versus previous guidance. 4. Adjusted EPS for 2025 estimated at $2.87-$2.94, up from earlier forecasts. 5. BSX stock down 0.98% at $105.13 amid regulatory and operational challenges.